Dedicated Antibody-Drug Conjugates (ADC) Facility

The Development of a Next Generation Antibody Drug Conjugate ADCПодробнее

[Webinar] Manufacturing concepts for antibody-drug conjugates | WebinarПодробнее

What are antibody-drug conjugates and how do they work against cancer?Подробнее

1.5 billion! AstraZeneca will build a facility in Singapore for ADCПодробнее

In-depth characterization of lysine-conjugated antibody-drug conjugates (ADCs) by multiplexed MS/MSПодробнее

How Do Antibody-drug conjugates ADCs Work?Подробнее

How Does It Work? | Antibody Drug ConjugatesПодробнее

Exploring antibody-drug conjugates (ADCs) in lung cancerПодробнее

What are Antibody Drug Conjugates (ADCs)?Подробнее

What are Antibody-drug Conjugates (ADCs)?Подробнее

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinomaПодробнее

Antibody-drug Conjugates - Where are we Going?Подробнее

👉Antibody-drug conjugates challenges and trendsПодробнее

Targeting tumours: Challenges of antibody-drug conjugatesПодробнее

Promising early results of a novel anti-CD123 antibody-drug conjugate in R/R BPDCNПодробнее

JK06, a biparatopic ADC in preclinical developmentПодробнее

Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody–drug conjugatesПодробнее

Characterization of Antibody-drug Conjugates (ADC)Подробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее